One-shot strategy: How to pick the right drug patent for maximum extension value
Most pharma teams don’t lose patent value because they miss the science. They lose it because they miss the timing—and the math—behind patent term extension.
Here’s the un…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion question it can’t afford to misread: Is the “clock” you’re counting really the one that matters?
In the patent world, timing isn’t just strategy—it’s survival. A few months can decide whether a blockbuster stays protected, whe…

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharmaceutical patent strategy is often discussed like a binary choice: cut, keep, or cash.
But in practice, it’s a portfolio decision—one that determines whether you’re funding growth or paying for “insurance” that never pays out.
In a recent piece fr…

The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t just a scheduling issue. It’s a revenue strategy. The moment a drug’s patent clock runs down, the market can shift from protected pricing to competitive pressu…